tiprankstipranks

BMO says Eylea court decision ‘modest negative’ for Regeneron

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in its Eylea biosimilar case “comes as expected by the Street and reads as a modest negative to Regeneron shares.” The decision adds incremental risk to the Eylea story with Amgen set to continue its at-risk launch of Pavblu, but with shares having re-rated with Eylea pressures appreciated at current levels, the firm likes the set-up into “a catalyst-filled 2025,” adds the analyst, who has an Outperform rating and $903 price target on Regeneron shares.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue